DexCom, Inc. (DXCM): Price and Financial Metrics
DexCom, Inc. (DXCM)
Today's Latest Price: $396.50 USD
Updated Oct 22 2:27pm
Add DXCM to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 142 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
DXCM Stock Summary
- Dexcom Inc's market capitalization of $37,132,657,563 is ahead of 94.6% of US-listed equities.
- With a price/earnings ratio of 181.4, Dexcom Inc P/E ratio is greater than that of about 96.11% of stocks in our set with positive earnings.
- Price to trailing twelve month operating cash flow for DXCM is currently 94.2, higher than 96.25% of US stocks with positive operating cash flow.
- Stocks with similar financial metrics, market capitalization, and price volatility to Dexcom Inc are ANSS, YNDX, ILMN, TTD, and NTES.
- DXCM's SEC filings can be seen here. And to visit Dexcom Inc's official web site, go to www.dexcom.com.
DXCM Stock Price Chart Interactive Chart >
DXCM Price/Volume Stats
| Current price | $396.50 | 52-week high | $456.23 |
| Prev. close | $387.84 | 52-week low | $145.23 |
| Day low | $385.86 | Volume | 303,573 |
| Day high | $398.25 | Avg. volume | 1,234,794 |
| 50-day MA | $405.05 | Dividend yield | N/A |
| 200-day MA | $349.41 | Market Cap | 37.96B |
DexCom, Inc. (DXCM) Company Bio
DexCom focuses on the design, development, and commercialization of continuous glucose monitoring systems for patients with diabetes. The company was founded in 1999 and is based in San Diego, California.
DXCM Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $396.50 | $361.57 | -8% |
Below please find a table outlining a discounted cash flow forecast for DXCM, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Dexcom Inc ranked in the 45th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. In terms of the factors that were most noteworthy in this DCF analysis for DXCM, they are:
- The stock's equity weight, or the proportion of capital from equity relative to debt, is 96. Its equity weight surpasses that of 74.34% of free cash flow generating stocks in the Healthcare sector.
- The company's compound free cash flow growth rate over the past 5.42 years comes in at 0.85%; that's greater than 89% of US stocks we're applying DCF forecasting to.
- The business' balance sheet reveals debt to be 4% of the company's capital (with equity being the remaining amount). Approximately merely 14.11% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -10% |
| 1% | -9% |
| 2% | -8% |
| 3% | -7% |
| 4% | -6% |
| 5% | -5% |
Want more companies with a valuation profile/forecast similar to that of Dexcom Inc? See AMED, MEDP, MCK, USPH, and HBIO.
Loading social stream, please wait...